HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Ketoprofen

HCID 3825
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
22071-15-4
Standard SMILES
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
InChIKey
DKYWVDODHFEZIM-UHFFFAOYSA-N
Molecular formula
C16H14O3
Average molar mass
254.28 g/mol
Monoisotopic mass
254.0942943

Overview

Ketoprofen is an oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2. It has a role as a non-steroidal anti-inflammatory drug, an antipyretic, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, a xenobiotic, an environmental contaminant and a drug allergen. It is a member of benzophenones and an oxo monocarboxylic acid. It is functionally related to a propionic acid.

Names & identifiers

Preferred name
Ketoprofen
IUPAC
2-(3-benzoylphenyl)propanoic acid
English name
Ketoprofen
Molecular formula
C16H14O3
Molecular weight
254.28

Names & synonyms

ketoprofen22071-15-42-(3-Benzoylphenyl)propanoic acid2-(3-Benzoylphenyl)propionic acidOrudisCapistenOruvailActronAlrheumatKetoprofeneAneolm-Benzoylhydratropic acid
Show more names
ProfenidKETOPROFEN USP2-(3-benzoylphenyl)-propionicaci(2RS)-2-(3-Benzoylphenyl)propanoic acid
3-Benzoylhydratropic acidIso-KKetoprofenoOrudis KTRP-19583SectorKetoprofenumKetorin

Database identifiers

CAS
22071-15-4
PubChem CID
3825
DTXSID
DTXSID6020771
ChEMBL
CHEMBL571
ChEBI
CHEBI:6128
UNII
90Y4QC304K
EC Number
244-759-8
Nikkaji
J3.468A

Properties

Computed structural propertiesFilling in

XLogP
3.1
Topological polar surface area
54.4 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
3
Rotatable bonds
4
Heavy atoms
19
Formal charge
0
Complexity
331

Experimental & physicochemical properties

Drugs · 4 items

DEA NFLIS-Drug Category -> Analgesics

Pharmaceuticals

Pharmaceuticals -> NSAIDs

Pharmaceutical

LogP · 2 items

3.2

3.12

Solubility2.13e-02 g/L
Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal Drugs · 3 items

FDA approved animal drugs -> Active ingredient

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Melting Point94 °C
Physical DescriptionSolid
Dissociation Constants · 4 items

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 0.1% (1 of 672) of reports.

Danger

H301 (99.7%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 672 reports by companies from 29 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

REACH registered substance: Ketoprofen (EC: 244-759-8)

Ketoprofen: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (99.7%)

Toxicology

Hepatotoxicity · 1 item

Prospective studies show that 1% to 2% of patients taking ketoprofen experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (>3 fold elevated) occur in

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ketoprofen

Chemistry & industry

Pharmacology

ATC Code · 5 items

M02AA10

M - Musculo-skeletal system

M - Musculo-skeletal system

QM - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding99% bound, primarily to albumin
Pharmacodynamics · 1 item

Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.

Mechanism of Action · 1 item

The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.

Biological Half-LifeConventional capsules: 1.1-4 hours <p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>
Metabolism/Metabolites · 2 items

Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.

Ketoprofen has known human metabolites that include Ketoprofen glucuronide.

FDA Pharmacological Classification · 6 items

90Y4QC304K

Related reactions

54 records
New reaction record
HRID 163579 reaction equation
HRID 163579As product
HRID 179402 reaction equation
HRID 179402As reactant
HRID 371111 reaction equation
HRID 371111As reactant
HRID 373356 reaction equation
HRID 373356As reactant
HRID 478092 reaction equation
HRID 478092As product
HRID 597796 reaction equation
HRID 597796As reactant
HRID 620971 reaction equation
HRID 620971As product
HRID 620972 reaction equation
HRID 620972As product
PreviousPage 1 of 7

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

3.98

4

3.8

4.45

Collision Cross Section · 4 items

155.4 Ų [M+H]+ [CCS Type: TW]

157.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

148.63 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

158.08 Ų [M+H]+

Physicochemical properties

Melting point
93 · 93-96°C
Boiling point
357.5 °C · 357.5°C (rough estimate)
Density
1.1565 · 1.1565 (rough estimate)
refractive index
1.56 · 1.5600 (estimate)
storage temp.
2 · 2-8°C
solubility
Slightly soluble in chloroform and methanol.
pka
5.94 · pKa 5.94(MeOH/H2O) (Uncertain)
form
solid
color
White to Off-White
biological source
synthetic
Water Solubility
209 mg/L · 209mg/L(room temperature)
Merck
14 · 14,5305
Major Application
forensics and toxicologypharmaceutical (small molecule)
InChI
1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
InChIKey
DKYWVDODHFEZIM-UHFFFAOYSA-N
SMILES
CC(C(O)=O)c1cccc(c1)C(=O)c2ccccc2
CAS DataBase Reference
22071 · 22071-15-4(CAS DataBase Reference)
EWG's Food Scores
1 · 1
NCI Dictionary of Cancer Terms
ketoprofen
FDA UNII
90 Y4QC304K · 90Y4QC304K
NCI Drug Dictionary
ketoprofen
ATC code
1 AE03,M01AE53,M02AA10 · M01AE03,M01AE53,M02AA10
NIST Chemistry Reference
Ketoprofen(22071-15-4)
EPA Substance Registry System
3 · Benzeneacetic acid, 3-benzoyl-.alpha.-methyl- (22071-15-4)
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Protein binding
99 % · 99%
Excreted unchanged in urine
1 % · <1%
Volume of distribution
0.1 · 0.1(L/kg)
Biological half-life
1.5 · 1.5-8 / 5-9
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
301 · H301
Precautionary statements
264 · P264-P270-P301+P310-P405-P501
PPE
2 · Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Hazard Codes
T
Risk Statements
25 · 25-36/37/38-23/24/25
Safety Statements
26 · 26-45-36/37/39
RIDADR
2811 · 2811
WGK Germany
3 · 3
RTECS
7570000 · UE7570000
TSCA
TSCA listed
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
29183000 · 29183000
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 OralAquatic · Acute Tox. 3 OralAquatic Acute 1Eye Irrit. 2Skin Irrit. 2
Toxicity
50 orally · LD50 orally in rats: 101 mg/kg (Ueno)
REACH Registrations
Active

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Ketoprofen

1.7

7.4

The usual dose of ketoprofen immediate-release capsules recommended for mild to moderate pain and dysmenorrhea is 25 to 50 mg every 6 to 8 hours as necessary.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 75 mg/day, Lowest Therapeutic Dose (LTD): 0.9 mg/kg-day, and Screening Dose: 0.0003 mg/kg-day.

12-Jan-22

Safety data

PPE
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
wgk
3
tsca
TSCA listed
rtecs
UE7570000
ridadr
2811
hs_code
29183000
Toxicity
LD50 orally in rats: 101 mg/kg (Ueno)
risk_code
25-36/37/38-23/24/25
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
T
safety_code
26-45-36/37/39
hazard_class
6.1(b)
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
III
Hazard statements
H301
REACH Registrations
Active
Hazard Classifications
Acute Tox. 3 OralAquatic Acute 1Eye Irrit. 2Skin Irrit. 2
Precautionary statements
P264-P270-P301+P310-P405-P501

KETOPROFEN

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Ketoprofen is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of ketoprofen is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2 items

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 3 items

Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.

In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.

Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]

Cellular LocationsCytoplasm
Metabolite PathwaysKetoprofen Action Pathway

Uses & manufacturing

UsesUse (kg) in Switzerland (2009): >250
Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
General Manufacturing InformationBenzeneacetic acid, 3-benzoyl-.alpha.-methyl-: INACTIVE
Applications · 6 items

DescriptionKetoprofen (3-benzoyl-α-methylphenylacetic acid) is a 2-arylpropionic acid potent non-steroidal anti-inflammatory drug. It was first synthesized by French chemist Rhone Poulenc in 1967. In 1973, it was introduced into France and the United States as an anti-inflammatory drug. It has good effects on rheumatism, rheumatoid arthritis, myelitis and gout, and its anti-inflammatory effect is stronger than that of ibuprofen. Ibuprofen. At the same dose, its anti-inflammatory and analgesic effect is 150 times that of aspirin, its antipyretic effect is 4 times that of indomethacin and 100 times that of aspirin. Because ketoprofen has high efficacy, short half-life, It has the advantages of simple metabolism and few and mild adverse reactions, and has been widely used in the treatment of various types of pain, inflammatory symptoms, colds and post-operative anti-inflammatory analgesia.

DescriptionKetoprofen is a chemical that comes in the form of a white crystalline powder; odorless or nearly odorless. It is very soluble in methanol, soluble in ethanol, acetone or ether, and almost insoluble in water. The melting point is about 93-96 °C. For the arylalkanoic acid compounds. Has analgesic, anti-inflammatory and antipyretic effects. The anti-inflammatory effect is stronger than that of ibuprofen, with less side effects and low toxicity. Oral and easily absorbed from the gastrointestinal tract. After 1 administration, the peak plasma concentration can be reached in about 0.5 to 2 hours. t 1/2 is 1.6 to 1.9 hours. In the blood and plasma protein binding force is extremely strong. The excretion rate from urine is 30% to 90% within 24 hours. Mainly excreted in the form of glucuronic acid conjugates. For rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and gout, etc.

UsesNatural Vitamin B12. analog

UsesKetoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.

UsesAnti-inflammatory; analgesic

General DescriptionKetoprofen (Orudis, Rhodis) and suprofen (Profenal) areclosely related to fenoprofen in their structures, properties,and indications. Even though ketoprofen has been approvedfor OTC use (Orudis KT, Actron), its GI side effects aresimilar to indomethacin, and therefore its useshould be closely monitored, especially in patients with GIor renal problems.

Upstream & downstream products

Upstream raw materials

Sulfuric acidIodomethane3-BenzoylphenylacetonitrileSodiumEthanol3-Benzoylphenylacetic acid

Downstream products

Phthalide3-Acetylbenzoic acid

Additional notes

DefinitionChEBI: An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.